Advertisement


Juliane Hörner-Rieber, MD, on Breast Cancer: Boosting Intensity-Modulated and Conventional Radiotherapies

2020 ASTRO Annual Meeting

Advertisement

Juliane Hörner-Rieber, MD, of Heidelberg University Hospital, discusses phase III results of the MINT trial, which showed that conventionally fractionated intensity-modulated radiotherapy with a simultaneous integrated boost was noninferior to three-dimensional conformal radiotherapy followed by a sequential boost for both local control and cosmesis in patients with breast cancer (Abstract 19).



Related Videos

Prostate Cancer

Linda G.W. Kerkmeijer, MD, PhD, on Prostate Cancer: Adding a Focal Boost to External-Beam Radiotherapy

Linda G.W. Kerkmeijer, MD, PhD, of the University Medical Center Utrecht and Radboud University Medical Center, discusses results from the phase III FLAME trial, which explored the question of whether biochemical disease–free survival can be improved by adding a focal boost to the intraprostatic lesion in whole-gland external-beam radiotherapy for patients with intermediate- and high-risk prostate cancers (Abstract 126).

Supportive Care

Jing Li, MD, PhD, on Brain Metastases: Stereotactic Radiosurgery vs Whole-Brain Radiation Therapy

Jing Li, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results showing the use of stereotactic radiosurgery in patients with 4 to 15 brain metastases, compared with whole-brain radiotherapy, may better preserve cognitive function and minimize the interruption of systemic therapy without compromising overall survival (Abstract 41).

Breast Cancer

Youssef Zeidan, MD, PhD, on HER2-Positive Breast Cancer: Deintensifying Radiation Therapy

Youssef Zeidan, MD, PhD, of the American University of Beirut Medical Center, discusses study findings showing that breast-conserving surgery, whole-breast irradiation, and trastuzumab offer effective local tumor control for patients with HER2-positive breast cancer. An additional radiation boost does not seem to further improve outcomes (Abstract 52).

Breast Cancer

Alphonse G. Taghian, MD, PhD, on Irradiation for Breast Cancer: Defining the Optimal Dose

Alphonse G. Taghian, MD, PhD, of Massachusetts General Hospital, reviews the 10-year follow-up of a dose-escalation trial studying accelerated partial-breast irradiation and discusses the optimal dose, adverse effects, and cosmetic outcomes (Abstract 25).

CNS Cancers

Jeff M. Michalski, MD, MBA, on Medulloblastoma and Radiation Treatment in Pediatric Patients

Jeff M. Michalski, MD, MBA, of the Washington University School of Medicine, discusses a Children’s Oncology Group study that confirmed data previously reported: Involved-field radiotherapy is noninferior to posterior fossa radiotherapy in patients with average risk-medulloblastoma. However, low-dose craniospinal irradiation is not as effective as standard-dose irradiation in younger children (Abstract 1).

Advertisement

Advertisement



Advertisement